BusinessFibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017By Nasdaq OMXSep 5, 2017, 8:06 PM UTC
BusinessaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology PipelineBy Nasdaq OMXAug 14, 2017, 8:06 PM UTC
BusinessFibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary FibrosisBy Nasdaq OMXAug 7, 2017, 8:50 PM UTC
BusinessFibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary FibrosisBy Nasdaq OMXMar 11, 2016, 1:00 PM UTC
